Needs Assessment/Learner’s Gap

Over the last 3 decades, ongoing advances in antiretroviral therapy (ART) for patients infected with human immunodeficiency virus (HIV) have improved outcomes across a diverse range of cohorts and clinical circumstances .1,2 As new data comparing existing drug regimens are published and new medications become available, HIV formularies must be periodically reviewed and adjusted to reflect both the evolving clinical evidence and various nonclinical parameters.3 Broad-based pharmacoeconomic assessment strategies should be used to optimize pharmacy-management practices within a value-based paradigm.4,5 In recognition of the needs of a multidisciplinary audience of HIV-formulary decision-makers, this webinar will bring together an expert faculty panel to review the latest clinical evidence for ART, available pharmacoeconomic data and their associated analytic instruments, and other key factors that can influence formulary changes and healthcare utilization. With an overall goal of improving HIV formularies, this educational program will help learners understand and address the complex relationships among healthcare cost, quality, and utilization.


  1. Jones J, et al. CROI 2017: Advances in antiretroviral therapy. Top Antivir Med. 2017;25(2): 51-67.
  2. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Accessed September 29, 2017.
  3. Vogenberg FR et al. Systemic market and organizational changes: Impact on P&T committees. P & T 2017;42(1):28-32.
  4. Fischer KE, et al. Link between process and appraisal in coverage decisions: An analysis with structural equation modeling. Med Decis Making. 2013;33(8):1009-1025.
  5. Malone DC. The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines. J Manag Care Pharm. 2005;11(4 Suppl):S7-S10.

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Discuss the latest efficacy, safety, and clinical, and healthcare-utilization outcomes data for new and emerging HIV regimens
  • Describe the effects of key patient, provider, and system-based factors on viral persistence, treatment durability, treatment adherence, and utilization outcomes among patients with HIV
  • Assess complex cost and quality concerns in HIV management using pharmacoeconomic instruments and strategies
  • Improve value-based HIV formulary decision-making to reflect recent clinical evidence, best-practice pharmacy-utilization processes, and prevailing pharmacoeconomic assessment strategies


Richard A. Elion, MD
Associate Clinical Professor of Medicine
George Washington University School of Medicine
Codirector, Department of Health Sexually Transmitted Disease Research
Washington, DC

James A. Jorgenson, RPh, MS, FASHP
Chief Executive Officer and Board Chair
Visante Inc. & Visante Ltd.
St. Paul, Minnesota

Robert LoNigro, MD, MS
EVP, Clinical Operations
Health Care Partners
Austin, Texas

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Integritas Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Purdue University College of Pharmacy designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.
Universal Activity Number (UAN): 0018-9999-17-088-H02-P, 1.0 contact hours (0.1 CEU).

Faculty Disclosure Statement

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored / provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue University and Integritas Communications staff have nothing to disclose.

Richard A. Elion, MD Consultant at Gilead; Speakers Bureau at Gilead and Jannsen; Honorarium Recipient at Gilead and Jannsen; Expert witness at Gilead.

James A Jorgenson, RRh, MS, FASHP Consultant at Visante, Inc. and Visante Ltd.; Speaker Bureau at Novartis.

Robert LoNigro, MD, MS Has nothing to disclose.

Required for Completion

Participants in this FREE activity must score 70% or better on the posttest and complete the online evaluation and request for credit. Pharmacist credits will be uploaded to CPE Monitor within 60 days. All other professions will receive their CE Certificates via email within 60 days.

Any accreditation questions may be directed to Dawn Sinclair at Purdue University via email Questions regarding CE credit and CPE Monitor should be directed to Heather Holley via email at

Begin Activity